



Patent Application
Attorney Docket No. PC10139A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Nancy J. Harper, et al. :

CPA OF APPLICATION NO.: 09/417,175, filed on October 11, 1999 : Examiner: Taylor V. Oh

CPA FILING DATE: Herewith : Group Art Unit: 1625

TITLE: Sertraline Oral Concentrate :

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No additional fees are believed due for this submission because it is being submitted before the mailing of the first Office Action in this continuing prosecution application. However, if any fees are due, the Commissioner is hereby authorized to charge the required sum to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 C.F.R. 1.97 and 1.17(p).

A prompt and favorable response is earnestly solicited.

Date: 1/28/03

Respectfully submitted,

Martha A. Gammill

Martha A. Gammill

Attorney for Applicant(s)

Reg. No. 31,820

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-5940

RECEIVED
FEB 03 2003
TECH CENTER 1600/2900